Showing results (331-340 of 378) with videos related to
Sort By:
Pageof 38
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2022
A Phase I Trial of CT900, a Novel α-Folate Receptor-Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian CancerSusana Banerjee, Vasiliki Michalarea, Joo Ern Ang, et al.The New England Journal of Medicine|March 12, 2004
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancerR Charles Coombes, Emma Hall, Lorna J Gibson, et al.European Journal of Cancer (Oxford, England : 1990)|May 10, 2024
Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trialPasquale Rescigno, Nuria Porta, Laura Finneran, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2021
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE TrialHannah L Rush, Laura Murphy, Alicia K Morgans, et al.International Journal of Radiation Oncology, Biology, Physics|March 20, 2019
MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder CancerAlexandra K Walker, Katalin Karaszi, Helen Valentine, et al.The Lancet. Oncology|June 25, 2016
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trialDavid Dearnaley, Isabel Syndikus, Helen Mossop, et al.Cancer Discovery|May 28, 2021
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B TrialSuzanne Carreira, Nuria Porta, Sara Arce-Gallego, et al.The Lancet. Oncology|October 31, 2020
Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion studyChristina Guo, Maxime Chénard-Poirier, Desamparados Roda, et al.Health Technology Assessment (Winchester, England)|October 27, 2022
Photodynamic versus white-light-guided resection of first-diagnosis non-muscle-invasive bladder cancer: PHOTO RCTRakesh Heer, Rebecca Lewis, Anne Duncan, et al.Nature Genetics|September 22, 2009
Multiple loci on 8q24 associated with prostate cancer susceptibilityAli Amin Al Olama, Zsofia Kote-Jarai, Graham G Giles, et al.Pageof 38